b'Report from the SSL Lead in CLRMReport from the SSL Lead in Oesophageal CancerSupportingandpromotingexistingstudiesisaImportantly,withthehelpofNickMaynardand crucialpartofthisrole.AUGISandBowelCancerJames Gossage we have secured a trainee research UK are actively supporting the EMT2 trial, a phase 3fellow to work with the NOGCA.He is funded 0.2 FTE placebo-controlled RCT looking at Omega-3 fish oilsfrom the RCS CEU and 0.8FTE from an RCS Research in patients with colorectal liver metastases. This is aFellowship.very straightforward study addressing an important question, and is an easy way to establish clinical trialBelowarehighlevelsummariesofactiveprojects.recruitmentanddeliveryasaroutinepartofyourListed first are observational/cohort studies followed clinical practice. Patients are very keen to take part,by interventional studies in early development.Not and benefit from lots of extra research nurse visitsincluded in this summary is the Oelixir Programme duringtheirinpatientstay.ItiseasytoparticipatewhichhasreachedinterviewstagewithCRUK eveninabusyclinicalunit,soifyoudlikemore(October4th)withextremelypositivepeer-review.informationonhowtogetinvolved,pleasegetinAUGIS is heavily invested in this programme.touch.Audit & Review of AntiReflux Operations & AlongwithBowelCancerUK,workcontinuestoWorkup developanonlinevideoeducationprogrammeforLead: Shameen JaunooMr Rob Jones patients and carers of those with advanced colorectalProfessor Tim Underwoodcancer.ThisprogrammehasaspecificfocusonCore Outcome set in AntirefLux InTerventIONs : empowering patients to drive their care. For example,The COALITION StudyWiththegeneroussupportofAUGISandBowelasking their local team about whether they have beenWork in the oesophageal cancer stream is progressingLead: Andrew Curry CancerUK,thepostofSpecialtyStudyLeadforreferred to a specialist HPB MDT, and whether theyapace.The first meeting of interested parties was Colorectal Liver Metastases was created in mid 2019. are eligible to take part in clinical trials. held in conjunction with the Pancreatic Cancer SSL,ProgROCPredicting outcomes and Prognosis of Keith Roberts at the RCS in February 2019.For theRadical treatment of Oesophagogastric CancerThe first 6 months have been busy. We have engagedThis is an exciting time for surgical research in the UK,oesophagealcancerthemeattendeeswereaskedLead: Saq Rahmanwith the ACPGBI/AUGIS IMPACT programme, whichwith a real emphasis on producing and delivering highto provide outline research ideas/areas prior to the aims to improve the management of patients withquality studies. The NHS offers enormous advantagesmeetingandthesewereusedtoseedbreak-outAddressing the Inconsistencies in Oesophageal advanced colorectal cancer across the UK. The nextforthedesignanddeliveryofresearch,meaningsessionswhereanumberofworkinggroupswereSquamous Cell Carcinoma Management cycle of this audit (IMPACT 3) will look at patterns ofwecananswerresearchquestionsinawaynoformed.A conscious decision was made to includeLead: Richard Evansreferral of patients with colorectal liver metastasesother country in the world can. By harnessing thesebenign OG disease as it pertains to cancer risk as I between MDTs, to map process across the UK. Thisopportunities, we can make sure that every patientfelt that it was important to engage the entire AUGISLASORSLAsting Symptoms after Oesophageal will provide quite granular data on local managementwe treat with advanced colorectal cancer is offeredconstituencyandnotrestrictactivitytoasmallResectional Surgerypractices for stage 4 disease. theopportunitytoparticipateinresearch,therebynumber of resectional centres.This will be importantLead: Sheraz Markarhelping us improve care in the future. for large-scale analyses of current practice and when DecembersawtheinauguralAUGIS/BowelCancerwecometoaskforrecruitmenttointerventionalLINX versus best medical therapy in patients with UKAdvancedColorectalCancerResearchSandpitstudies. Barretts oesophagus(pictured opposite).Rob Jones Lead: James Gossage/Tim UnderwoodSurgical Specialty Lead in CLRM TwoAssociateSSLshavebeenappointed;Natalie Over40attendees,includingtrialmethodologists,Blencowe and Sheraz Markar.They are the highestEndoscopy versus surgery for the treatment of T1b specialistsinnoveltrialdesign,patients,funders,qualitydevelopingresearcherswithexistingoesophageal adenocarcinomasurgeons and oncologists met to develop plans forportfoliosincludingtrialmethodologyandmulti- Lead: Tim Underwoodnovelandinnovativestudiestoanswersomeofinstitutional research.There is regular and excellent thekeyquestionssurroundingthemanagementcommunication between me and the Associate SSLs. Professor Tim Underwoodof metastatic colorectal cancer, many of which hadAdditionally, we have linked well with James GossageSurgical Specialty Lead in OG Cancerbeen highlighted in last years AUGIS Delphi exercise.to develop a programme that will hopefully deliver An early follow-up meeting is planned in Spring 2020,clear UK standards and guidelines for UK OG surgery whereworkinggroupsfromthesandpitwillbringlinked to high quality research.We have a number back a more developed study protocol with a view toofactivejointprojects(seebelow)andweareat developing preliminary data and applying for fundingthe outline planning stage for an AUGIS Consensus by the end of the year. If you missed the sandpit inMeeting on perioperative care for oesophagectomy December,haveaburningideaforastudy,orarepatients.We envisage that this will develop state-interested in getting involved in broader research inof-the-art guidelines for UK practice and also set the advanced colorectal cancer, please do contact me byagenda for an adaptive Multi-arm Multi-stage (MAMS) email (robjones@liv.ac.uk). trial to rapidly evaluate a series of interventions (e.g. inspiratory muscle training, peri-op steroids, post-op PPV, post-op feeding).24 AUGIS Winter 2019 Newsletter AUGIS Winter 2019 Newsletter 25'